Register a trial

Please note the ANZCTR will be unattended from Friday 20 December 2024 for the holidays. The Registry will re-open on Tuesday 7 January 2025. Submissions and updates will not be processed during that time.

Registering a new trial?

To achieve prospective registration, we recommend submitting your trial for registration at the same time as ethics submission.

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been endorsed by the ANZCTR. Before participating in a study, talk to your health care provider and refer to this information for consumers
Trial details imported from ClinicalTrials.gov

For full trial details, please see the original record at https://clinicaltrials.gov/study/NCT06430801




Registration number
NCT06430801
Ethics application status
Date submitted
21/05/2024
Date registered
28/05/2024

Titles & IDs
Public title
A Study to Evaluate the Efficacy and Safety of Tulisokibart (MK-7240) in Participants With Moderate to Severe Crohn's Disease (MK-7240-008)
Scientific title
A Phase 3, Randomized, Double-Blind, Placebo-Controlled Program to Evaluate the Efficacy and Safety of Tulisokibart in Participants With Moderately to Severely Active Crohn's Disease
Secondary ID [1] 0 0
MK-7240-008
Secondary ID [2] 0 0
7240-008
Universal Trial Number (UTN)
Trial acronym
Linked study record

Health condition
Health condition(s) or problem(s) studied:
Crohn's Disease 0 0
Condition category
Condition code
Oral and Gastrointestinal 0 0 0 0
Inflammatory bowel disease
Inflammatory and Immune System 0 0 0 0
Other inflammatory or immune system disorders
Oral and Gastrointestinal 0 0 0 0
Crohn's disease

Intervention/exposure
Study type
Interventional
Description of intervention(s) / exposure
Treatment: Drugs - IV Tulisokibart
Treatment: Drugs - SC Tulisokibart
Other interventions - IV Placebo
Other interventions - SC Placebo

Experimental: Study 1: High Dose Induction, High Dose Maintenance - Participants receive high dose intravenous (IV) tulisokibart, followed by a high dose subcutaneous (SC) tulisokibart regimen.

Experimental: Study 1: High Dose Induction, Low Dose Maintenance - Participants receive high dose IV tulisokibart, followed by a low dose SC tulisokibart regimen.

Experimental: Study 1: Low Dose Induction, Low Dose Maintenance - Participants receive low dose IV tulisokibart, followed by a low dose SC tulisokibart regimen.

Placebo comparator: Study 1: Placebo - Participants receive IV placebo, followed by an SC placebo regimen.

Experimental: Study 1: High Dose Extension - Participants receive a high dose SC tulisokibart regimen. Participants may be enrolled in this arm after completing participation in their original arm, if they meet protocol-specific prerequisites.

Experimental: Study 1: Low Dose Extension - Participants receive a low dose SC tulisokibart and placebo regimen. Participants may be enrolled in this arm after completing participation in their original arm, if they meet protocol-specific prerequisites.

Experimental: Study 2: High Dose Induction - Participants receive high dose IV tulisokibart.

Experimental: Study 2: Low Dose Induction - Participants receive low dose IV tulisokibart.

Placebo comparator: Study 2: Placebo - Participants receive IV placebo.

Experimental: Study 2: High Dose Extension - Participants receive a high dose SC tulisokibart regimen. Participants may be enrolled in this arm only after completing participation in their original arm, if they meet protocol-specific prerequisites.

Experimental: Study 2: Low Dose Extension - Participants receive a low dose SC tulisokibart regimen. Participants may be enrolled in this arm only after completing participation in their original arm, if they meet protocol-specific prerequisites.


Treatment: Drugs: IV Tulisokibart
Humanized monoclonal antibody that binds human tumor necrosis factor-like cytokine 1A (TL1A), administered intravenously

Treatment: Drugs: SC Tulisokibart
Humanized monoclonal antibody that binds human TL1A, administered subcutaneously

Other interventions: IV Placebo
Placebo matching IV tulisokibart

Other interventions: SC Placebo
Placebo matching SC tulisokibart
Intervention code [1] 0 0
Treatment: Drugs
Intervention code [2] 0 0
Other interventions
Comparator / control treatment
Control group

Outcomes
Primary outcome [1] 0 0
Study 1 [US/FDA Only]: Percentage of Participants Achieving Clinical Remission per Crohn's Disease Activity Index (CDAI) Score at Week 52
Timepoint [1] 0 0
Week 52
Primary outcome [2] 0 0
Study 1 [EU/EMA Only]: Percentage of Participants Achieving Clinical Remission per Stool Frequency and Abdominal Pain Score at Week 52
Timepoint [2] 0 0
Week 52
Primary outcome [3] 0 0
Study 1: Percentage of Participants Achieving Endoscopic Response at Week 52
Timepoint [3] 0 0
Week 52
Primary outcome [4] 0 0
Study 1: Percentage of Participants Achieving Clinical Remission per CDAI Score at Week 12
Timepoint [4] 0 0
Week 12
Primary outcome [5] 0 0
Study 1: Percentage of Participants Achieving Clinical Remission per Stool Frequency and Abdominal Pain Score at Week 12
Timepoint [5] 0 0
Week 12
Primary outcome [6] 0 0
Study 1: Percentage of Participants Achieving Endoscopic Response at Week 12
Timepoint [6] 0 0
Week 12
Primary outcome [7] 0 0
Study 1: Percentage of Participants Who Experienced an Adverse Event (AE)
Timepoint [7] 0 0
Up to approximately 52 weeks
Primary outcome [8] 0 0
Study 1: Percentage of Participants who Discontinue Study Intervention due to an AE
Timepoint [8] 0 0
Up to approximately 52 weeks
Primary outcome [9] 0 0
Study 2 [US/FDA Only]: Percentage of Participants Achieving Clinical Remission per CDAI Score at Week 12
Timepoint [9] 0 0
Week 12
Primary outcome [10] 0 0
Study 2 [EU/EMA Only]: Percentage of Participants Achieving Clinical Remission per Stool Frequency and Abdominal Pain Score at Week 12
Timepoint [10] 0 0
Week 12
Primary outcome [11] 0 0
Study 2: Percentage of Participants Achieving Endoscopic Response at Week 12
Timepoint [11] 0 0
Week 12
Primary outcome [12] 0 0
Study 2: Percentage of Participants Who Experienced an AE
Timepoint [12] 0 0
Up to approximately 12 weeks
Primary outcome [13] 0 0
Study 2: Percentage of Participants who Discontinue Study Intervention due to an AE
Timepoint [13] 0 0
Up to approximately 12 weeks
Secondary outcome [1] 0 0
Study 1 [US/FDA Only]: Percentage of Participants Achieving Clinical Remission per Stool Frequency and Abdominal Pain Score at Week 12
Timepoint [1] 0 0
Week 12
Secondary outcome [2] 0 0
Study 1 [EU/EMA Only]: Percentage of Participants Achieving Clinical Remission per CDAI Score at Week 12
Timepoint [2] 0 0
Week 12
Secondary outcome [3] 0 0
Study 1: Percentage of Participants with Decrease of =100 Points in CDAI Score from Baseline to Week 12
Timepoint [3] 0 0
Week 12
Secondary outcome [4] 0 0
Study 1: Mean Change from Baseline in Functional Assessment of Chronic Illness Therapy - Fatigue (FACIT-Fatigue) Score at Week 12
Timepoint [4] 0 0
Baseline and Week 12
Secondary outcome [5] 0 0
Study 1: Percentage of Participants Achieving Endoscopic Remission at Week 12
Timepoint [5] 0 0
Week 12
Secondary outcome [6] 0 0
Study 1 and 2: Percentage of Participants in Diagnostic Assay Positive (Dx+) Subpopulation Achieving Clinical Remission per CDAI at Week 12
Timepoint [6] 0 0
Week 12
Secondary outcome [7] 0 0
Study 1 and 2: Percentage of Participants in Diagnostic Assay Positive (Dx+) Subpopulation Achieving Endoscopic Response at Week 12
Timepoint [7] 0 0
Week 12
Secondary outcome [8] 0 0
Study 1 [US/FDA Only]: Percentage of Participants Achieving Clinical Remission per Stool Frequency and Abdominal Pain Score at Week 52
Timepoint [8] 0 0
Week 52
Secondary outcome [9] 0 0
Study 1: Percentage of Participants Achieving Clinical Remission per CDAI Score at Week 52
Timepoint [9] 0 0
Week 52
Secondary outcome [10] 0 0
Study 1: Percentage of Participants with Decrease of =100 Points in CDAI Score from Baseline to Week 52
Timepoint [10] 0 0
Week 52
Secondary outcome [11] 0 0
Study 1: Percentage of Participants Achieving Endoscopic Remission at Week 52
Timepoint [11] 0 0
Week 52
Secondary outcome [12] 0 0
Study 1: Percentage of Participants Achieving Sustained Clinical Remission per CDAI at Both Week 12 and Week 52
Timepoint [12] 0 0
Week 12 and Week 52
Secondary outcome [13] 0 0
Study 1: Percentage of Participants Achieving Corticosteroid-Free Clinical Remission per CDAI Score at Week 52
Timepoint [13] 0 0
Week 52
Secondary outcome [14] 0 0
Study 1: Percentage of Participants Achieving Corticosteroid-Free Clinical Remission per Stool Frequency and Abdominal Pain Score at Week 52
Timepoint [14] 0 0
Week 52
Secondary outcome [15] 0 0
Study 1: Percentage of Participants Achieving Clinical Remission per Stool Frequency, Abdominal Pain Score, and Endoscopic Remission at Week 52
Timepoint [15] 0 0
Week 52
Secondary outcome [16] 0 0
Study 1: Percentage of Participants Achieving Clinical Remission per CDAI and Endoscopic Remission at Week 52
Timepoint [16] 0 0
Week 52
Secondary outcome [17] 0 0
Study 1: Mean Change from Baseline in FACIT-Fatigue Score at Week 52
Timepoint [17] 0 0
Baseline and Week 52
Secondary outcome [18] 0 0
Study 1: Mean Change from Baseline in Inflammatory Bowel Disease Questionnaire (IBDQ) Score at Week 52
Timepoint [18] 0 0
Baseline and Week 52
Secondary outcome [19] 0 0
Study 1: Percentage of Participants with Ulcer-Free Endoscopy at Week 52
Timepoint [19] 0 0
Week 52
Secondary outcome [20] 0 0
Study 2 [US/FDA Only]: Percentage of Participants Achieving Clinical Remission per Stool Frequency and Abdominal Pain Score at Week 12
Timepoint [20] 0 0
Week 12
Secondary outcome [21] 0 0
Study 2 [EU/EMA Only]: Percentage of Participants Achieving Clinical Remission per CDAI Score at Week 12
Timepoint [21] 0 0
Week 12
Secondary outcome [22] 0 0
Study 2: Percentage of Participants with Decrease of =100 Points in CDAI Score from Baseline to Week 12
Timepoint [22] 0 0
Week 12
Secondary outcome [23] 0 0
Study 2: Mean Change from Baseline in FACIT-Fatigue Score at Week 12
Timepoint [23] 0 0
Baseline and Week 12
Secondary outcome [24] 0 0
Study 2: Percentage of Participants Achieving Endoscopic Remission at Week 12
Timepoint [24] 0 0
Week 12
Secondary outcome [25] 0 0
Study 2: Mean Change from Baseline in Inflammatory Bowel Disease Questionnaire (IBDQ) Score at Week 12
Timepoint [25] 0 0
Baseline and Week 12
Secondary outcome [26] 0 0
Study 2: Percentage of Participants with Decrease of =100 Points in CDAI Score from Baseline to Week 6
Timepoint [26] 0 0
Week 6
Secondary outcome [27] 0 0
Study 2: The percentage of Participants with Ulcer-Free Endoscopy at Week 12
Timepoint [27] 0 0
Week 12

Eligibility
Key inclusion criteria
The main inclusion and exclusion criteria include but are not limited to the following:



* Has had a diagnosis of CD at least 3 months before study.
* Has moderately to severely active CD.
* Demonstrated inadequate response, loss of response, or intolerance to one or more of the following categories of drugs: oral locally acting steroids, systemic steroids, immunomodulators, biologic and/or small molecule advanced therapies.
Minimum age
16 Years
Maximum age
75 Years
Sex
Both males and females
Can healthy volunteers participate?
No
Key exclusion criteria
* Has diagnosis of ulcerative colitis (UC) or indeterminate colitis.
* Has CD isolated to the stomach, duodenum, jejunum, or perianal region, without colonic and/or ileal involvement.
* Currently has any of the following complications of CD: suspected or diagnosed with intra-abdominal or perianal abscess, known symptomatic stricture or colonic stenosis not passable in endoscopy, fulminant colitis, toxic megacolon, or any other manifestation that might require surgery while enrolled in the study.
* Has current stoma or need for colostomy or ileostomy.
* Is missing >2 segments of the following 5 segments: terminal ileum, right colon, transverse colon, sigmoid and left colon, and rectum.
* Has been diagnosed with short gut or short bowel syndrome, or any other uncontrolled chronic diarrhea besides Crohn's disease.
* Has surgical bowel resection within 3 months of study.
* Has prior or current gastrointestinal dysplasia.
* Has chronic infection requiring ongoing antimicrobial treatment.
* Has a history of cancer (except fully treated non-melanoma skin cell cancers or cervical carcinoma in situ after complete surgical removal) within the last 5 years.
* Is infected with Hepatitis B virus (HBV), Hepatitis C virus (HCV), or human immunodeficiency virus (HIV).
* Has active tuberculosis.
* Has confirmed or suspected coronavirus disease of 2019 (COVID-19) infection.
* Prior exposure to tulisokibart (MK-7240, PRA023) or another anti-anti-TL1A antibody.

Study design
Purpose of the study
Treatment
Allocation to intervention
Randomised controlled trial
Procedure for enrolling a subject and allocating the treatment (allocation concealment procedures)
Methods used to generate the sequence in which subjects will be randomised (sequence generation)
Masking / blinding
Blinded (masking used)
Who is / are masked / blinded?
The people receiving the treatment/s
The people administering the treatment/s
The people assessing the outcomes
The people analysing the results/data
Intervention assignment
Parallel
Other design features
Phase
Phase 3
Type of endpoint/s
Statistical methods / analysis

Recruitment
Recruitment status
Recruiting
Data analysis
Reason for early stopping/withdrawal
Other reasons
Date of first participant enrolment
Anticipated
Actual
5/06/2024
Date of last participant enrolment
Anticipated
Actual
Date of last data collection
Anticipated
8/10/2032
Actual
Sample size
Target
1200
Accrual to date
Final
Recruitment in Australia
Recruitment state(s)
NSW
Recruitment hospital [1] 0 0
Concord Repatriation General Hospital-Gastroenterology and Liver Services ( Site 3202) - Concord
Recruitment postcode(s) [1] 0 0
2139 - Concord
Recruitment outside Australia
Country [1] 0 0
United States of America
State/province [1] 0 0
Alabama
Country [2] 0 0
United States of America
State/province [2] 0 0
California
Country [3] 0 0
United States of America
State/province [3] 0 0
Colorado
Country [4] 0 0
United States of America
State/province [4] 0 0
Connecticut
Country [5] 0 0
United States of America
State/province [5] 0 0
District of Columbia
Country [6] 0 0
United States of America
State/province [6] 0 0
Florida
Country [7] 0 0
United States of America
State/province [7] 0 0
Georgia
Country [8] 0 0
United States of America
State/province [8] 0 0
Illinois
Country [9] 0 0
United States of America
State/province [9] 0 0
Indiana
Country [10] 0 0
United States of America
State/province [10] 0 0
Kansas
Country [11] 0 0
United States of America
State/province [11] 0 0
Louisiana
Country [12] 0 0
United States of America
State/province [12] 0 0
Michigan
Country [13] 0 0
United States of America
State/province [13] 0 0
Missouri
Country [14] 0 0
United States of America
State/province [14] 0 0
New York
Country [15] 0 0
United States of America
State/province [15] 0 0
North Carolina
Country [16] 0 0
United States of America
State/province [16] 0 0
Ohio
Country [17] 0 0
United States of America
State/province [17] 0 0
Pennsylvania
Country [18] 0 0
United States of America
State/province [18] 0 0
Rhode Island
Country [19] 0 0
United States of America
State/province [19] 0 0
Tennessee
Country [20] 0 0
United States of America
State/province [20] 0 0
Texas
Country [21] 0 0
United States of America
State/province [21] 0 0
Virginia
Country [22] 0 0
United States of America
State/province [22] 0 0
Washington
Country [23] 0 0
Canada
State/province [23] 0 0
Ontario
Country [24] 0 0
Canada
State/province [24] 0 0
Quebec
Country [25] 0 0
Chile
State/province [25] 0 0
Region M. De Santiago
Country [26] 0 0
Chile
State/province [26] 0 0
Valparaiso
Country [27] 0 0
China
State/province [27] 0 0
Beijing
Country [28] 0 0
China
State/province [28] 0 0
Chongqing
Country [29] 0 0
China
State/province [29] 0 0
Fujian
Country [30] 0 0
China
State/province [30] 0 0
Guangdong
Country [31] 0 0
China
State/province [31] 0 0
Hebei
Country [32] 0 0
China
State/province [32] 0 0
Henan
Country [33] 0 0
China
State/province [33] 0 0
Hubei
Country [34] 0 0
China
State/province [34] 0 0
Jiangsu
Country [35] 0 0
China
State/province [35] 0 0
Shanghai
Country [36] 0 0
China
State/province [36] 0 0
Sichuan
Country [37] 0 0
China
State/province [37] 0 0
Zhejiang
Country [38] 0 0
France
State/province [38] 0 0
Alpes-Maritimes
Country [39] 0 0
France
State/province [39] 0 0
Aquitaine
Country [40] 0 0
France
State/province [40] 0 0
Bouches-du-Rhone
Country [41] 0 0
France
State/province [41] 0 0
Bourgogne
Country [42] 0 0
France
State/province [42] 0 0
Champagne-Ardenne
Country [43] 0 0
France
State/province [43] 0 0
Doubs
Country [44] 0 0
France
State/province [44] 0 0
Haute-Garonne
Country [45] 0 0
France
State/province [45] 0 0
Hauts-de-Seine
Country [46] 0 0
France
State/province [46] 0 0
Languedoc-Roussillon
Country [47] 0 0
France
State/province [47] 0 0
Loire-Atlantique
Country [48] 0 0
France
State/province [48] 0 0
Meurthe-et-Moselle
Country [49] 0 0
France
State/province [49] 0 0
Nord
Country [50] 0 0
France
State/province [50] 0 0
Rhone
Country [51] 0 0
France
State/province [51] 0 0
Somme
Country [52] 0 0
France
State/province [52] 0 0
Val-de-Marne
Country [53] 0 0
France
State/province [53] 0 0
Paris
Country [54] 0 0
Germany
State/province [54] 0 0
Nordrhein-Westfalen
Country [55] 0 0
Germany
State/province [55] 0 0
Rheinland-Pfalz
Country [56] 0 0
Germany
State/province [56] 0 0
Schleswig-Holstein
Country [57] 0 0
Germany
State/province [57] 0 0
Brandenburg
Country [58] 0 0
Hungary
State/province [58] 0 0
Bekescsaba
Country [59] 0 0
Hungary
State/province [59] 0 0
Veszprem
Country [60] 0 0
Hungary
State/province [60] 0 0
Budapest
Country [61] 0 0
Israel
State/province [61] 0 0
Ashkelon
Country [62] 0 0
Israel
State/province [62] 0 0
Haifa
Country [63] 0 0
Israel
State/province [63] 0 0
Holon
Country [64] 0 0
Israel
State/province [64] 0 0
Jerusalem
Country [65] 0 0
Israel
State/province [65] 0 0
Kfar Saba
Country [66] 0 0
Israel
State/province [66] 0 0
Petah Tikva
Country [67] 0 0
Israel
State/province [67] 0 0
Ramat Gan
Country [68] 0 0
Italy
State/province [68] 0 0
Lazio
Country [69] 0 0
Italy
State/province [69] 0 0
Lombardia
Country [70] 0 0
Italy
State/province [70] 0 0
Sicilia
Country [71] 0 0
Italy
State/province [71] 0 0
Verona
Country [72] 0 0
Italy
State/province [72] 0 0
Bologna
Country [73] 0 0
Italy
State/province [73] 0 0
Milano
Country [74] 0 0
Italy
State/province [74] 0 0
Roma
Country [75] 0 0
Japan
State/province [75] 0 0
Aichi
Country [76] 0 0
Japan
State/province [76] 0 0
Chiba
Country [77] 0 0
Japan
State/province [77] 0 0
Fukuoka
Country [78] 0 0
Japan
State/province [78] 0 0
Hiroshima
Country [79] 0 0
Japan
State/province [79] 0 0
Hokkaido
Country [80] 0 0
Japan
State/province [80] 0 0
Hyogo
Country [81] 0 0
Japan
State/province [81] 0 0
Ibaraki
Country [82] 0 0
Japan
State/province [82] 0 0
Iwate
Country [83] 0 0
Japan
State/province [83] 0 0
Kanagawa
Country [84] 0 0
Japan
State/province [84] 0 0
Mie
Country [85] 0 0
Japan
State/province [85] 0 0
Saitama
Country [86] 0 0
Japan
State/province [86] 0 0
Shizuoka
Country [87] 0 0
Japan
State/province [87] 0 0
Tokyo
Country [88] 0 0
Japan
State/province [88] 0 0
Yamanashi
Country [89] 0 0
Japan
State/province [89] 0 0
Kagoshima
Country [90] 0 0
Japan
State/province [90] 0 0
Kyoto
Country [91] 0 0
Japan
State/province [91] 0 0
Okayama
Country [92] 0 0
Japan
State/province [92] 0 0
Osaka
Country [93] 0 0
Japan
State/province [93] 0 0
Saga
Country [94] 0 0
Japan
State/province [94] 0 0
Toyama
Country [95] 0 0
Japan
State/province [95] 0 0
Yamagata
Country [96] 0 0
Korea, Republic of
State/province [96] 0 0
Kang-won-do
Country [97] 0 0
Korea, Republic of
State/province [97] 0 0
Kyonggi-do
Country [98] 0 0
Korea, Republic of
State/province [98] 0 0
Pusan-Kwangyokshi
Country [99] 0 0
Korea, Republic of
State/province [99] 0 0
Seoul
Country [100] 0 0
Korea, Republic of
State/province [100] 0 0
Taegu-Kwangyokshi
Country [101] 0 0
Korea, Republic of
State/province [101] 0 0
Taejon-Kwangyokshi
Country [102] 0 0
Netherlands
State/province [102] 0 0
Gelderland
Country [103] 0 0
Netherlands
State/province [103] 0 0
Noord-Brabant
Country [104] 0 0
Netherlands
State/province [104] 0 0
Noord-Holland
Country [105] 0 0
Netherlands
State/province [105] 0 0
Zuid-Holland
Country [106] 0 0
Netherlands
State/province [106] 0 0
Groningen
Country [107] 0 0
Netherlands
State/province [107] 0 0
Utrecht
Country [108] 0 0
Portugal
State/province [108] 0 0
Faro
Country [109] 0 0
Portugal
State/province [109] 0 0
Lisboa
Country [110] 0 0
Portugal
State/province [110] 0 0
Viana do Castelo
Country [111] 0 0
Romania
State/province [111] 0 0
Bucuresti
Country [112] 0 0
Romania
State/province [112] 0 0
Cluj
Country [113] 0 0
Romania
State/province [113] 0 0
Mures
Country [114] 0 0
Romania
State/province [114] 0 0
Timis
Country [115] 0 0
Sweden
State/province [115] 0 0
Stockholms Lan
Country [116] 0 0
Switzerland
State/province [116] 0 0
Basel-Stadt
Country [117] 0 0
Switzerland
State/province [117] 0 0
Berne
Country [118] 0 0
Switzerland
State/province [118] 0 0
Sankt Gallen
Country [119] 0 0
Switzerland
State/province [119] 0 0
Zurich
Country [120] 0 0
Taiwan
State/province [120] 0 0
Hsinchu
Country [121] 0 0
Taiwan
State/province [121] 0 0
Taipei
Country [122] 0 0
Taiwan
State/province [122] 0 0
Taoyuan
Country [123] 0 0
Ukraine
State/province [123] 0 0
Ivano-Frankivska Oblast
Country [124] 0 0
Ukraine
State/province [124] 0 0
Kyivska Oblast
Country [125] 0 0
Ukraine
State/province [125] 0 0
Lvivska Oblast
Country [126] 0 0
Ukraine
State/province [126] 0 0
Vinnytska Oblast
Country [127] 0 0
Ukraine
State/province [127] 0 0
Volynska Oblast
Country [128] 0 0
Ukraine
State/province [128] 0 0
Kyiv
Country [129] 0 0
United Kingdom
State/province [129] 0 0
England

Funding & Sponsors
Primary sponsor type
Commercial sector/industry
Name
Merck Sharp & Dohme LLC
Address
Country

Ethics approval
Ethics application status

Summary
Brief summary
Trial website
Trial related presentations / publications
Public notes

Contacts
Principal investigator
Name 0 0
Medical Director
Address 0 0
Merck Sharp & Dohme LLC
Country 0 0
Phone 0 0
Fax 0 0
Email 0 0
Contact person for public queries
Name 0 0
Toll Free Number
Address 0 0
Country 0 0
Phone 0 0
1-888-577-8839
Fax 0 0
Email 0 0
Trialsites@msd.com
Contact person for scientific queries

Data sharing statement
Will individual participant data (IPD) for this trial be available (including data dictionaries)?
Yes
What data in particular will be shared?
http://engagezone.msd.com/doc/ProcedureAccessClinicalTrialData.pdf
When will data be available (start and end dates)?
Available to whom?
Available for what types of analyses?
How or where can data be obtained?
IPD available at link: http://engagezone.msd.com/ds_documentation.php


What supporting documents are/will be available?

No Supporting Document Provided



Results publications and other study-related documents

No documents have been uploaded by study researchers.


Results not provided in https://clinicaltrials.gov/study/NCT06430801